Pfizer Inc. is reviewing options including a sale of its women’s health portfolio as the U.S. pharmaceutical giant seeks to focus on developing treatments with higher growth potential, according to Bloomberg News.
To read the entire story, you must be logged in.
Please log in now or register with us.
